Eglin EG-009 has been approved by the FDA to enter phase 1 clinical trials to treat new coronary pneumonia.

Shenzhen Eglin Pharmaceutical Co., Ltd. announced on September 23, 2020 U.S. Eastern Time, the U.S. FDA officially approved the company for the treatment of neo-coronavirus pneumonia oral capsule EG-009 clinical first phase application.
application for the IND was made under the CTAP procedure set up by the FDA specifically for new coronavirus pneumonia.
review of the entire IND took 26 natural days.
EG-009 is one of Eglin Pharmaceuticals' nine research and development pipelines for treating cytokine storms caused by neocyto pneumonia.
cytokine storms are one of the leading causes of death in patients with neocytocytitis, and the oral preparation EG-009 is mainly used to prevent and treat cytokine release sydrome caused by neocytovirus.
EG-009 research and development will offer new hope for reducing the mortality rate of patients with neo-crown pneumonia at a time when the global epidemic of new coronary pneumonia continues.
.